Weblogs

The French periodical PARIS MATCH published an extensive document on the fight against malaria with Artemisia annua and Artemisia afra. And the dubious role WHO plays.

https://www.parismatch.com/Actu/Sante/Artemisia-et-paludisme-la-sante-entre-les-mains-des-Africains-1577250

Amiodarone which is used to control irregular heartbeat also has a protective effect in malaria. It triggers eryptosis and the clearance of malaria infected erythrocytes. In Plasmodium berghei infected mice amiodarone injections increased the survival. It is interesting to note that amiodarone is also active against other tropical diseases like Chagas or Leishmaniasis, both in vitro and in vivo, probably by disrupting the parasites' Ca(2+) homeostasis,

Vaccines blocking the invasion of malaria sporozoites failed so far, after 30 years of efforts, millions spent, and disastrous human clinical trials. The efforts and the millions are now focused on vaccines blocking transmission by gametocytes. The results are not yet encouraging but the updated Malaria Vaccine Technology Roadmap foresees that there will be a TBV vaccine available in 2030. The update was necessary as the program launched by WHO in 2000 ( TDR/RBM/MAL/VAC/2000.1) has not yet progressed very far.

In 2001 WHO posted a statement on their home page, without signatures, without references: « Due to the instability of artemisinin in raw materials of Artemisia annua L, the leaves need to be stored in cool conditions — preferably below 20°C. Most malaria endemic countries have warm climates and people generally lack access to refrigeration, so it is difficult for patients to keep artemisinin-containing tea bags under 20°C in their homes” A statement not substantiated by scientific papers. Cui bono?

Our associations immediately gathered available data which prove the contrary